Pirouette Pharma GTM brain

Pirouette Pharma develops the OnePush auto-injector and drug-device programs for pharmaceutical partners and patients who self-inject.

category

Drug delivery and auto-injector platforms

market profile

  • text: Pharmaceutical companies seek self-injection devices that can differentiate medicines and reduce administration burden.
  • text: Pirouette describes itself as clinical-stage and is developing both partnered and proprietary drug-device programs.

personas

  • title: VP of pharmaceutical business development or partnerships
    pains:
    • Needs an injection device partner that can differentiate an existing or pipeline therapy.
    • Must evaluate co-development, manufacturing readiness and regulatory responsibilities.
  • title: Drug product or combination product development leader
    pains:
    • Must match a delivery device to a drug formulation, dose and route of administration.
    • Needs evidence of usability and reliable delivery before a combination product can advance.
  • title: Patient experience or commercial brand leader
    pains:
    • Needle anxiety and complexity can undermine patients' willingness to start or continue self-injection.
    • Needs credible evidence of patient preference and adherence before making brand claims.

icp

  • text: Pharmaceutical and biotech companies developing injectable chronic therapies, including oncology and HIV medications, for home administration.
  • text: Drug developers seeking partner-ready device differentiation for novel or established medicines; company-size thresholds are not stated.
  • text: Organizations exploring rescue medicine and first-responder use are an adjacent opportunity, subject to product development and regulatory requirements.

message pillars

  • text: Make injectable medicine simpler to administer.
  • text: Design around patient comfort and confidence.
  • text: Create a differentiated partner experience for home injection.

objections

  • objection: Is the device approved and ready for commercial deployment with our drug?
    response: Treat the platform as clinical-stage; verify current regulatory status and define drug-specific studies and responsibilities with the company.
  • objection: Can it deliver our particular formulation and dose reliably?
    response: Request feasibility data for formulation, volume, route and container compatibility before selecting a co-development program.
  • objection: Can manufacturing support a large launch?
    response: Review manufacturing validation, quality systems and capacity milestones in diligence; the company says it is investing in automation.

competitors

  • name: SHL Medical
    website: https://www.shl-medical.com/products/autoinjectors/dai
    why: Develops auto-injector platforms with pharmaceutical partners.
  • name: Ypsomed
    website: https://www.ypsomed.com/en/expertise/partner-network
    why: Develops self-injection device platforms and supports drug-device combination projects.
  • name: Owen Mumford
    why: Auto-injector manufacturer competing for pharmaceutical device programs.

keywords

  • pharmaceutical auto injector partner
  • hidden needle drug delivery
  • combination drug device development
  • self injection device platform
  • patient centric autoinjector
  • chronic therapy injection adherence
  • 505(b)(2) injectable device

voice

  • Patient-centered
  • Clinical and engineering-led
  • Partnership-oriented

signals

  • text: A pharmaceutical company is developing a self-administered injectable or biosimilar and evaluating device partners.
  • text: A mature injectable brand is seeking a differentiated administration experience or improved patient persistence.

pricing

model: unknown

motion

sales_led

channels

  • LinkedIn
  • partnerships
  • industry events

confidence

medium

Founders

  • name: Conor Cullinane
    title: Founder
    role: Founder
    bio: Conor obtained a PhD in Medical Engineering & Medical Physics at MIT and Harvard Medical School in the Health Sciences and Technology Program, and a BS in aeronautical engineering from Clarkson University. He is interested in leading engineering teams to successful technology implementations, not by ordering action to be taken, but rather taking action and motivating others to do the same. He has expertise in human factors engineering, medical engineering, medical physics, and startups.
  • name: Matthew Kane
    title: Founder
    role: Founder
    bio: Matthew received a B.S. in aeronautical and mechanical engineering from Clarkson University. He received a MSc in Aerospace Engineering from the University of Notre Dame. He is the COO of Pirouette Medical where he is primarily responsible for FDA Interactions, regulatory requirements, project management, quality management and design analysis. He has previous experience with fluid dynamics, turbomachinery, design, and testing. He loves learning and finding unique engineering solutions.
  • name: Elijah Kapas
    title: Founder
    role: Founder
    bio: Eli received a dual BS in Mechanical and Civil engineering from Clarkson University. Experience in design as well as implementation allows for key insight to user interfaces and workability. Eli is the CTO for Pirouette Medical and is responsible for device design and intellectual property. He has worked across multiple industries in roles ranging from quality to supervision and knows how to leverage the key strengths of team members to be successful.

Back to YC companies